

Number	Title	First Name	Last Name	Affiliation	Country
1	Geographic correlation between the number of COVID-19 cases and the number of overseas travelers in Japan, January-February 2020	Keita	Wagatsuma	Niigata University	Japan
2	Risk factors of viral RNAemia and its association with clinical prognosis among patients with severe COVID-19	Hui	Li	China-Japan Friendship Hospital	China
3	Study on the Diagnostic Value of Blood Inflammatory Indicators in COVID-19	Lin	Zhao	China-Japan Friendship Hospital	China
4	A Rapid Review of the Asymptomatic Proportion of PCR-Confirmed SARS-CoV-2 Infections in Community Settings	Sarah	Beale	University College London	United Kingdom
5	The SymptomSurvey: Patient and Caretaker Perspectives on COVID-19 Symptom Severity and the Expected Impact of Antivirals and Vaccines	Myriam	Harrabi	Vienna Vaccine Safety Initiative	United States
6	Understanding patients' acceptability of self-collection of various clinical specimens to inform clinical diagnosis of COVID-19	Ngai Yung	Tsang	The University of Hong Kong	Hong Kong SAR, China
7	Quantitative proteomics characterization of respiratory viruses-exposed human primary T cells reveals host-pathogen interactions and therapy targets	Jiapei	Yu	School of Medicine, Tsinghua University	China
8	Transcriptional profiling of immune and inflammatory responses in the context of SARS-CoV-2 fungal superinfection in a human airway epithelial model	Olivier	Terrier	Centre International de Recherche en Infectiologie (CIRI)	France
9	Establishment of a novel real time PCR method to detect live SARS-CoV-2 in clinical samples	Xiaohui	Zou	Chinese-Japan friendship hospital	China
10	The role of serological diagnosis in the study of the COVID-19 pathogenesis	Iuliia	Desheva	Institute of Experimental Medicine	Russian Federation
11	Characterization of spike activation and temperature dependence of SARS-CoV-2 and other human coronaviruses	Manon	Laporte	Rega Institute; KU Leuven	Belgium
12	ICAM3 is a likely receptor for SARS CoV2 Entry	Theresa	Deisher	AVM Biotechnology, LLC	United States

13	Searching for antiviral strategies against a broad range of beta-CoV: Spike and Polymerase proteins as promising anti-CoV targets.	Ines	Figueiredo-Nunes	National Health Institute Doutor Ricardo Jorge (INSA)	Portugal
14	Antiviral potential of distinct heparins against SARS-CoV-2 in vitro	Aline	da Rocha Matos	Fiocruz	Brazil
15	Guanosine as RNA Replication Blocker for Therapeutic Treatment of COVID 19	Maurice	Devaraj	NA	India
16	AT-527, the oral prodrug of a guanosine nucleotide analog, is a potent in vitro inhibitor of SARS-CoV-2	Steven	Good	Atea Pharmaceuticals, Inc.	United States
17	Plasma and tissue disposition of AT-527 and its active triphosphate metabolite in monkeys: implications for dose selection for patients with COVID-19	Xiao-Jian	Zhou	Atea Pharmaceuticals, Inc	United States
18	Pre-planned meta-analysis of randomised trials of sofosbuvir-daclatasvir, to evaluate clinical benefits and survival	Andrew	Hill	University of Liverpool	United Kingdom
19	Interpreting in-vitro data for sofosbuvir against SARS-CoV-2: cell lineage is key	Jacob	Levi	NHS, UCLH, Intensive Care	United Kingdom
20	The in vitro antiviral activity of the anti-hepatitis C virus drugs daclatasvir and sofosbuvir against SARS-CoV-2.	Carolina de Queiroz	Sacramento	Fiocruz	Brazil
21	Role of 1'-Ribose Cyano Substitution for Remdesivir to Effectively Inhibit Nucleotide Addition and Proofreading in SARS-CoV-2 Viral RNA Replication	Peter	Cheung	Chinese Academy of Sciences	China
22	Betulonic Acid Derivatives Interfering with Coronavirus Replication via the Nsp15 Endoribonuclease	Annelies	Stevaert	Rega Institute for Medical Research, KU Leuven	Belgium
23	A Broad Inhibitor of Coronavirus Replication Acting via the Nsp15 Endoribonuclease	Benjamin	Van Loy	Rega Institute for Medical Research, KU Leuven	Belgium
24	Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry	Jerome	Deval	Aligos Therapeutics	United States
25	Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV2 Coronavirus	Anny	Slama-Schwok	INSERM U938, CRSA, Sorbonne University	France
26	Long-Acting Intramuscular Injection of Niclosamide as a Broad Host-Directed Therapeutic Against SARS-CoV-2 and Other Viral Infections	Daniel	Jang	Daewoong Pharmaceutical	Korea, Republic of
27	Acute, Suprapharmacologic Dexamethasone Mobilizes Natural Killer T and Cytotoxic T cells for COVID-19 ARDS	Theresa	Deisher	AVM Biotechnology, LLC	United States
28	Low-to-moderate dose corticosteroids Treatment in Hospitalized Adults With COVID-19	Zhibo	Liu	China-Japan Friendship Hospital	China